|
|||||||
|
|||||||
|
Papers, abstracts, presentations, posters and
webcasts emanating from the audit Abstracts
DUK Glasgow 2016 P Sen Gupta, VS Johal, BM McGowan, RS Drummond, SA Amiel and REJ Ryder. Early (6 month) metabolic and body weight effects of duodenal exclusion with endobarrier as an adjunct to glucagon-likepeptide-1 (GLP-1) therapy in sub optimally controlled Type 2 diabetes. Diabetic Medicine 2016. 33 (Suppl 1): Abstract A26. (need link to abstract
ENDO 2016 Piya Sen Gupta, Barbara MC McGowan, Stephanie A Amiel, Robert EJ Ryder, Sebastian T Lugg , Russell S Drummond. One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion Using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) Therapy in Suboptimally Controlled Type 2 Diabetes: A Randomised Controlled Trial. Proceedings of ENDO Conference, Boston, USA, April 2016. (need link to abstract
DDW 2016 E Fogden, P Sen Gupta, M Anderson, B Hayee, RS Drummond, BM McGowan, SA Amiel, REJ Ryder. One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) therapy in Suboptimally Controlled Type 2 Diabetes: a Randomised Controlled Trial. Proceedings of the Digestive Diseases Week (DDW), San Diego, USA May 2016. (need link to abstract
DDW 2016 Hayee B, Sen Gupta P, Anderson M, Fogden E, Roy AA, Butler DB, Bajwa RS, Amiel SA, Ryder REJ. Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity. Proceedings of the Digestive Diseases Week (DDW), San Diego, May 2016. (need link to abstract
ESGAR 2016 V. Hedayati, P. Sen Gupta, B.M. McGowan, R.E. Ryder, F. Rubino, S.A. Amiel, S.M. Ryan. Contrast-enhanced computed tomography (CT) assessment of the positioning of a novel intestinal bypass liner device (Endobarrier) for type 2 diabetes: correlation of the degree of metabolic response with the extent of intestinal exclusion. Proceedings of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), Prague, June 2016. (need link to abstract
ADA New Orleans 2016 Robert E.J. Ryder, Vikramdeep S. Johal, Holly M. Murphy, Zoe S. Littlewood, Russell S. Drummond, Barbara M. McGowan, Stephanie A. Amiel, Piya Sen Gupta. The Effect of 1-Year’s Endoscopic Proximal Intestinal Exclusion Using Endobarrier on 10-Year Cardiovascular Risk in Type 2 Diabetes. Diabetes 2016 Jul; 65 (Supplement 1): 263-OR. (need link to abstract
EASD Munich 2016 P Sen Gupta, RS Drummond, BM McGowan, SA Amiel, REJ Ryder. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like-peptide-1 (GLP-1) therapy: a randomised controlled trial. Diabetologia 2016, Vol.59 Supplement1: Abstract 569.
DUK Manchester 2017 P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and REJ Ryder. One year efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion therapy using the Endobarrier device: institution of the UK's first National Health Service Endobarrier service for Type 2 diabetes and obesity. Diabetic Medicine 2017. 34 (Suppl 1): Abstract A26. (need link to abstract
DUK Manchester 2017 M Yadagiri, MH Lang, AAS Mohamed, N Nathani, AB Rajasekaran, JP Bleasdale, EN Fogden, MR Anderson, PS Gupta and REJ Ryder. Endoscopic proximal intestinal exclusion with Endobarrier bringing simultaneous benefit to both diabesity and obstructive sleep apnoea (OSA) requiring overnight continuous positive airway pressure ventilation (CPAP): three case reports. Diabetic Medicine 2017. 34 (Suppl 1): Abstract P224. (need link to abstract
DUK Manchester 2017 P Sen Gupta, RS Drummond, BM McGowan, B Hayee, T Dew, RP Vincent, CW le Roux, JJ Holst, SA Amiel and REJ Ryder. The interaction o endoscopic proximal intestinal exclusion therapy using Endobarrier with glucagon‐like peptide‐1 (GLP‐1) therapy rapidly improves Type 2 diabetes by increasing fasting and postprandial satiety. Diabetic Medicine 2017. 34 (Suppl 1): Abstract P423. (need link to abstract
ADA San Diego 2017 Robert E.J. Ryder, Mahender Yadagiri, John P. Bleasdale, Edward N. Fogden, Mark R. Anderson, Piya Sen Gupta. Maintenance of Efficacy after Endobarrier in UK First National Health Service (NHS) Endobarrier Service. Diabetes 2017 Jul; 66 (Supplement 1): 2110-P. (need link to abstract
EASD Lisbon 2017 A. Basu, P. Sen Gupta, M. Yadagiri, B.M. McGowan, R.S.Drummond, T.H. Jones, S.A. Amiels, R.E.J, Ryder. Endoscopic proximal intestinal exclusion with Endobarrier therapy is associated with improvement in gonadal function in obese men with diabetes. Diabetologia 2017, Vol.60 Supplement1: Abstract 858.
EASD Lisbon 2017 REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and P Sen Gupta. Efficacy, safety, tolerability and sustainability outcomes of endoscopic proximal intestinal exclusion with Endobarrier: 1st UK NHS Endobarrier service for diabesity. Diabetologia 2017, Vol.60 Supplement1: Abstract 701.
BSG 2017 M Anderson, PSen Gupta, M Yadagiri, S Irwin, W Burbridge, N Taylor, R Allden, M Wilson, H Gandhi, J Bleasdale, R Ryder, E Fogden. Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk’s first nhs endobarrier service for diabesity. British Society of GastroEnterology abstract published in Gut 2017;66: http://dx.doi.org/10.1136/gutjnl-2017-314472.1.
ABCD Autumn 2017 M Yadagiri, N Ashman, J Adams, F Kinney, M Lang, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder. Seven out of the first eight patients in the ABCD EndoBarrier® in obstructive sleep apnoea(End-OSA) study no longer require continuous positive airway pressure ventilation(CPAP) after 3 months treatment with EndoBarrier. Oral presentation, ABCD Autumn Meeting 2017. (need link to abstract
DUK 2018 REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and P Sen Gupta. UK’s first NHS Endobarrier service for diabesity: Outcomes in the first 30 patients to reach six months after explanation of the device. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P416. (need link to abstract
DUK 2018 M Yadagiri, N Ashman, F Kinney, M Lang, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton and REJ Ryder. Preliminary results of the Association of British Clinical Diabetologists sponsored Endobarrier in Type 2 diabetes/prediabetes with obstructive sleep apnoea study. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P418. (need link to abstract
DUK 2018 S Armstrong, P Sen Gupta, SA Amiel, RS Drummond, BM McGowan, REJ Ryder and MW Pennington. A UK cost-effectiveness analysis of the Endobarrier device in patients with Type 2 diabetes and obesity. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P425. (need link to abstract
ABCD Spring 2018 Drummond RS, Timmons J, Talla M, Sen Gupta P, Ryder REJ. Liver Abscess secondary to a duodenal-jejunal bypass liner (DJBL) successfully treated with antibiotics but without removal of the device. Poster, ABCD Spring Meeting 2018. https://bjd-abcd.com/index.php/bjd/article/download/285/538
ADA 2018 Robert E.J. Ryder, Mahender Yadagiri, Susan P. Irwin, Wyn Burbridge, Melanie C. Wyres, Hardeep Gandhi, Melissa L. Cull, Rachel Allden, John Bleasdale, Edward Fogden, Mark Anderson and Piya Sen Gupta. U.K. First National Health Service (NHS) Endobarrier (EB) Service—Outcomes in First 38 Patients to Reach Six Months after Device Explant. Diabetes 2018 Jul; 67 (Supplement 1): 2087-P. https://doi.org/10.2337/db18-2087-P
ADA 2018 Mahender Yadagiri, Fiona Y. Kinney, Natalie Ashman, Michael H. Lang, Edward Fogden, Mark Anderson, John Bleasdale, Christopher Walton, Michael A. Greenstone and Robert E. Ryder. Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results. Diabetes 2018 Jul; 67 (Supplement 1): 2071-P. https://doi.org/10.2337/db18-2071-P
ADA 2018 Robert E.J. Ryder, Lynne Munro, Jessica J. McMaster, Justin Bessell, Jeanine M. Bascomb, Jane E. Collins, Lilian Kow, Jacob Chisholm, Harold Sourij, Peter N. Pferschy, Julian P. Teare, John C. Mason, James P. Byrne, Melanie C. Wyres, Melissa L. Cull, Wyn Burbridge, Susan P. Irwin, Mahender Yadagiri, Edward Fogden,Mark Anderson, Piya Sen Gupta and Marek Benes. First Risk–Benefit Data from the Worldwide Endobarrier Registry. Diabetes 2018 Jul; 67 (Supplement 1): 2097-P. https://doi.org/10.2337/db18-2097-P
ADA 2018 Piya Sen Gupta, Stephanie Armstrong, Srephanie A. Amiel, Robert E. Ryder and Mark W. Pennington. Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes. Diabetes 2018 Jul; 67 (Supplement 1): 1250-P. https://doi.org/10.2337/db18-1250-P
EASD Berlin 2018 EN Fogden, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, MR Anderson and REJ Ryder. Impact of proximal intestinal exclusion with EndoBarrier on key metabolic parameters and cardiovascular risk (UKPDS risk engine) in the first NHS-UK EndoBarrier service. Diabetologia 2018, Vol.61 Supplement1: Abstract 711.
DUK Liverpool 2019 REJ Ryder , M Yadagiri , SP Irwin , W Burbridge , T Bashir , RA Allden , JP Bleasdale , EN Fogden , MR Anderson and P Sen Gupta. UK first National Health Service (NHS) EndoBarrier service for advanced Type 2 diabetes and obesity: One year outcomes in all patients treated. Diabetic Medicine 2019. 36 (Suppl 1): Abstract A2. (need link to abstract
DUK Liverpool 2019 M Yadagiri, F Kinney, J Adams, A Mohammed, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton and REJ Ryder. One year results of Association of British Clinical Diabetologists (ABCD) EndoBarrier in Type 2 diabetes/prediabetes with obstructive sleep apnoea study. Diabetic Medicine 2019. 36 (Suppl 1): Abstract P356. (need link to abstract
ABCD Spring 2019 REJ Ryder, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Cockwell. Improvement in renal function in the first UK NHS EndoBarrier service for uncontrolled diabesity. Poster, ABCD Spring Meeting 2019. (need link to abstract
WCITD 2019 P Sen Gupta, BM McGowan, RS Drummond, SA Amiel and REJ Ryder. Evaluation of the efficacy and safety of endoscopically achieved proximal intestinal exclusion as an adjunct to glucagon-likepeptide-1 therapy in diabesity: REVISE-Diabesity clinical trial. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019. (need link to abstract
WCITD 2019 REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta. UK first National Health Service (NHS) Endobarrier Service for uncontrolled DIABESITY shows the metabolic improvements 6-months after Endobarrier removal are well maintained. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019. (need link to abstract
WCITD 2019 M Yadagiri, F Kinney, J Adams, N. Ashman, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder. Impact of Endobarrier on need for continuous-positive-airway-pressure ventilation (CPAP) in diabetes/pre-diabetes with obstructive sleep apnoea (OSA) study: current data at Endobarrier removal and 6-months later. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019. (need link to abstract
WCITD 2019 B. Ryder, M. Lynne, H. Frydenberg, S. Fishman, R. Cohen, C. de Jonge, J. Greve, J. Bascomb, J. Bessell, J. McMaster, G. Holtman, G. Rich, J. Collins, L. Kow, P. Pferschy, H. Sourij, J. Byrne, J. Mason, J. Teare, M. Benes. Duodenal Jejunal bypass liner for DIABESITY – Risk versus benefit data from the Association of British Clinical DIiabetologists (ABCD) worldwide Endobarrier Registry. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019. (need link to abstract
ADA San Fransico 2019 Robert E.J. Ryder, Piya Sen Gupta, Mahender YadagiriI, Susan P. Irwin, Wyn Burbridge, Tahira Bashir, Melanie C. Wyres, Rachael Allden, John Bleasdale, Edward Fogden and Mark Andersoj. UK First National Health Service (NHS) Endobarrier (EB) Service: Maintenance of Improvement One Year after Device Removal. Diabetes 2019 Jun; 68 (Supplement 1): 2047-P. https://doi.org/10.2337/db19-2047-P
ADA San Fransisco 2019 Mahender Yadagiri, Fiona Y. Kinney, Natalie Ashman, Emma S. Sharratt, Cheryl Greenwood, Jessica Adams, Melanie C. Wyres, Michael H. Lang, John Bleasdale, Edward Fogden, Mark Anderson, Christopher Walton, Michael A. Greenstone and Robert E. Ryder. Endobarrier (EB) in Diabetes/Prediabetes with Obstructive Sleep Apnea (OSA) Study—Maintenance of Improvement after EB Removal. Diabetes 2019 Jun; 68 (Supplement 1): 2080-P. https://doi.org/10.2337/db19-2080-P
.
Posters |
Register
for the Endobarrier worldwide Registry Access the Endobarrier registry on-line tool Download first visit data entry form that matches the on-line tool Download follow up visit data entry form that matches the on-line tool |
||||||
|
Working to support high quality diabetes care in the UK |
|||||||
|
|
|||||||
